NFKB1 and cancer: Some studies have reported that TKIs such as imatinib can suppress NF-κB signaling in certain types of cancer cells, leading to reduced cell survival and proliferation.584 On the other hand, there are also reports suggesting that some TKIs can induce NF-κB activity.